A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

NCT01495065 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Community-acquired Infection

Interventions

DRUG: GSK2251052 750 mg
DRUG: GSK2251052 1500 mg
DRUG: GSK2251052 1500 mg BID
DRUG: GSK2251052 2250 mg
DRUG: GSK2251052 3000 mg
DRUG: GSK2251052 0.9% saline

Sponsor

GlaxoSmithKline